AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaHealth Care
Respiratory Tract Infections5-alpha Reductase InhibitorsAzasteroidsAnthropology, CulturalPericardiumAcute DiseaseAldehyde ReductaseHeart Conduction SystemSeasonsElectrocardiographyAnti-Bacterial Agents
InhibitorsDutasterideBenign prostatic h5ARIAlpha blockersDisease progressionClinicalPatientsRiskPreventDrugsStandardMonthsManagementDutasterideFinasterideLUTSInnovative therapiesDiscontinuationReductase inhibitor therapyPharmacological therapyCombination therapyInhibitorProstateBenignTreatmentLong-term
Inhibitors8
  • The use of anti-androgen drugs, like 5-alpha reductase inhibitors (5ARIs), could protect from severe pulmonary disease. (medrxiv.org)
  • Prostate care for EP usually begins with a regiment of drugs called 5-alpha reductase inhibitors or 5ARIs. (prostatehealthtips.com)
  • Additionally, PCPs prescribed α-blockers more frequently than 5α-reductase inhibitors (5ARIs), even though 5ARIs have been shown to be more effective in management of disease progression of the prostate over time. (biomedcentral.com)
  • Patients with enlarged prostates are treated with 5-alpha reductase inhibitors (5ARIs) are used as a frontline therapy for BPH andto shrink prostate volume by blocking the conversion of testosterone to dihydrotestosterone (DHT). (ghenry.info)
  • 4. For patients with benign prostatic hypertrophy (BPH) is combination therapy with alpha-blockers and 5-alpha reductase inhibitors (5ARI) more efficacious than alpha-blockers alone? (cfpclearn.ca)
  • Pharmacological BPH therapy protocols advocate the use of α-blockers (ABs) and 5α-reductase inhibitors (5ARI), individually or in combination, as well as phosphodiesterase-5 (PDE5) inhibitors, individually or concomitantly with ABs. (medscape.com)
  • Finasteride belongs to a medication class, 5-alpha-reductase inhibitors (5ARIs), which have come under scrutiny by the United States and Canada because of their possible link to mental health issues. (cosmetictown.com)
  • Could the 5α-reductase inhibitors (5ARIs) dutasteride and finasteride increase the risk of developing male breast cancer? (bernsteinmedical.com)
Dutasteride3
  • Exposure BPH treatment with 5ARIs (finasteride/dutasteride) in the last six months. (medrxiv.org)
  • 5ARIs are prominently available as finasteride and dutasteride, with both exhibiting similar clinical effects. (medscape.com)
  • Where appropriate, this capsule may be used to substitute concomitant Tamsulosin Hydrochloride and Dutasteride in existing dual therapy to simplify treatment. (medeasy.health)
Benign prostatic h1
  • Objective To determine whether men who received 5ARIs for benign prostatic hyperplasia (BPH) have a lower risk of hospitalization for COVID-19. (medrxiv.org)
5ARI2
  • Among the 943 males, 45 (4.77%) patients were exposed to chronic 5ARI therapy. (medrxiv.org)
  • However, one-third of men are resistant to 5ARI therapies. (auanet.org)
Alpha blockers1
  • At best, adding 5ARIs to alpha-blockers reduces the number of men with clinical progression (5% compared to 10% on alphablocker alone), and the number needing BPH surgery (2% compared to 8% on alpha-blocker alone). (cfpclearn.ca)
Disease progression2
  • The 5ARIs are considered disease-modifying agents because they work by decreasing dihydrotestosterone (DHT) levels, which slow disease progression by causing regression of the prostate epithelial cells. (biomedcentral.com)
  • The AUA guidelines recommend use of 5ARIs to prevent disease progression in men with EP [ 2 ]. (biomedcentral.com)
Clinical1
  • However, clinical studies in the 1990s reported that despite the amelioration of LUTS, adverse effects of BPH drug therapy began to surface. (medscape.com)
Patients6
  • Main Outcome(s) and Measure(s) The primary outcome was to compare the prevalence of male patients chronically exposed to 5ARIs, who required hospitalization for COVID-19, with the one of age-matched males in Lombardy. (medrxiv.org)
  • Several new hormone therapies (abiraterone, enzalutamide, apalutamide, and darolutamide) have been approved for metastatic patients. (prostatecancer.news)
  • It divides patients into 9 risk groups (3 low (IA-C), 3 intermediate (IIA-C), and 3 high (IIIA-C)) based on how likely they are to die of their prostate cancer after all their therapies. (prostatecancer.news)
  • For most patients with localized prostate cancer, their cancer is not likely to be lethal after well-done therapies, at least not for a long time. (prostatecancer.news)
  • What patients want to know is which therapy gives them the best chance of a cure and what side effects they can reasonably expect - their predicted outcomes are more important than their prognosis . (prostatecancer.news)
  • received reports of male breast cancer developing in patients using 5ARIs, which are known to alter the normal estrogen/testosterone balance. (bernsteinmedical.com)
Risk3
  • In 2016, we looked at the Candiolo risk stratification system for radiation therapy. (prostatecancer.news)
  • The men using 5ARIs had an 88\\% higher risk of harming themselves during the first18 months of use. (cosmetictown.com)
  • In addition to the risk of depression, a separate study spotlighted the concern of erectile dysfunction with the use of 5ARIs. (cosmetictown.com)
Prevent1
  • 5ARIs cause the inhibition of 5α-reductase enzymes and prevent the conversion of non-active forms testosterone to DHT, the androgen steroid compound mainly responsible for the initial and subsequent enlargement of the prostate gland. (medscape.com)
Drugs2
  • New therapies, drugs and surgeries are less invasive and are highly successful in treating prostate conditions. (prostatehealthtips.com)
  • A greater understanding of detrusor physiology as well as the development of effective drugs for solving the dynamic and static components of the obstruction in the prostate and bladder neck have paved the path for the ubiquity of pharmacological therapy for BPH. (medscape.com)
Standard2
  • It shows a patient's prognosis of dying in 5 years or 10 years from prostate cancer (Prostate Cancer-Specific Mortality - PCSM) after availing themselves of whatever standard therapies they choose. (prostatecancer.news)
  • Over the past two decades, the standard of treatment has shifted from surgery to drug therapy. (medscape.com)
Months1
  • Physicians need more awareness regarding the decrease of PSA due to 5ARIs of 50% after 6 to 12 months use which can mask high-grade prostate cancer. (pfsfoundation.org)
Management1
  • Because enlarged prostate (EP) was viewed historically as a symptomatic condition, management of voiding symptoms with α-blockers was often the goal of therapy. (biomedcentral.com)
Dutasteride2
  • 9. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. (nih.gov)
  • 13. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. (nih.gov)
Finasteride2
  • On the other hand, discontinuation rates were lower for combination therapy (18 %) compared to finasteride (24 %) and doxazosin (27 %) monotherapy. (medscape.com)
  • Another aspect of this discussion also involves consideration for the possible existence of persistent sexual side effects and anxiety/depressive symptoms reported with the use of 5ARis like finasteride (27,28). (montrosefire.net)
LUTS5
  • [ 19-21 ] Current guidelines recommend the use of ABs and 5ARIs as monotherapy or in combination for the treatment of BPH-associated LUTS. (medscape.com)
  • BPH/LUTS therapies. (nih.gov)
  • 12. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. (nih.gov)
  • Mixture therapy with -blockers and 5ARIs provides shown effective in reducing LUTS, lowering TPV, and reducing the chance of disease development in comparison to treatment with an individual medicine or placebo [8,9]. (liveconscience.com)
  • Mixture therapy with -blockers and 5ARI NR2B3 continues to be recommended for sufferers with moderate-to-severe LUTS and enlarged prostates in the rules for BPH/LUTS administration [10,11]. (liveconscience.com)
Innovative therapies2
  • Despite the massive research effort over the past two decades to identify innovative therapies, current management of severe sepsis includes eradication of infection through source control and microbial therapy, aggressive and targeted shock resuscitation with fluid administration, correction of anemia, vasopressor support, modest inotropic therapy, and compulsive supportive care to manage organ dysfunction and to avoid complications. (eurekaselect.com)
  • Our associates work on the development and production of innovative therapies and high-quality pharmaceutical formulations for worldwide distribution. (montrosefire.net)
Discontinuation3
  • and confirmed a 2-year discontinuation rate of 10-20 % of patients under 5ARIs. (medscape.com)
  • 4. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH). (nih.gov)
  • Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. (finasterideinfo.org)
Reductase inhibitor therapy1
  • 14. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. (nih.gov)
Pharmacological therapy2
  • Studies on patient adherence on pharmacological therapy for the treatment of hypertension have shown that 50 % of patients discontinue their medication while two-thirds of patients that stay on treatment seem to lower their drug doses. (medscape.com)
  • 1. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. (nih.gov)
Combination therapy4
  • Is Combination Therapy Better Than Monotherapy? (medscape.com)
  • 11. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia. (nih.gov)
  • 16. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH. (nih.gov)
  • Annual use prevalence and incidence rates for each drug class and for the combination therapy (CT) were calculated according to age for the entire study period. (unich.it)
Inhibitor1
  • Purpose To research long-term therapeutic effects and individual adherence to a mixture therapy of the 5-reductase inhibitor and an -blocker also to identify factors behind withdrawal from medication in sufferers with clinical harmless prostatic hyperplasia (BPH). (liveconscience.com)
Prostate1
  • Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is accompanied by side effects affecting health-related quality of life (HRQL). (researchgate.net)
Benign2
  • 6. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms. (nih.gov)
  • 7. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia. (nih.gov)
Treatment1
  • A smaller sized TPV after short-term mixture treatment was among the elements that caused drawback from mixture therapy. (liveconscience.com)
Long-term2
  • Conclusions BPH sufferers receiving long-term mixture therapy demonstrated significant improvement in every measured variables. (liveconscience.com)
  • This research aims to measure the long-term restorative effects of mixture therapy at an individual middle in Hualien Region, Taiwan. (liveconscience.com)